Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

EGFR mutation unique to glioblastoma linked to lack of response

AACR 2012

Published: 13 Apr 2012

Views: 4782

Rating:

Save

Dr Ingo Mellinghoff - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Mellinghof presents on epidermal growth factor receptor mutations that occur in glioblastoma and how they differ from those that occur in lung cancers. This finding, which was presented at the AACR 2012 Annual Meeting, may explain the lack of response to epidermal growth factor receptor inhibitors seen in glioblastoma.

Related Videos

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain

Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ASCO 2024: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ASCO 2024: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Osimertinib success in locally advanced EGFR-mutated NSCLC

Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA

Osimertinib success in locally advanced EGFR-mutated NSCLC ( Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA )

Adagrasib improves on docetaxel in previously treated NSCLC

Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado

Adagrasib improves on docetaxel in previously treated NSCLC ( Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado )

More from ecancer